Advertisement
U.S. markets closed
S&P Futures
6,011.75 +24.75 (+0.41%) Dow Futures
44,622.00 +227.00 (+0.51%) Nasdaq Futures
20,952.00 +102.25 (+0.49%) Russell 2000 Futures
2,438.20 +24.60 (+1.02%) Crude Oil
71.24 0.00 (0.00%) Gold
2,718.60 +6.40 (+0.24%)
Kiora Pharmaceuticals, Inc. (KPRX)
NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Follow
At close: 04:00PM EST
After hours:
| Previous Close | 3.3000 |
| Open | 3.4038 |
| Bid | 2.3800 x 200 |
| Ask | 4.3200 x 200 |
| Day's Range | 3.2200 - 3.4038 |
| 52 Week Range | 3.0000 - 8.9820 |
| Volume | |
| Avg. Volume | 23,664 |
| Market Cap | 10.11M |
| Beta (5Y Monthly) | -0.29 |
| PE Ratio (TTM) | 3.21 |
| EPS (TTM) | 1.0500 |
| Earnings Date | Nov 08, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 40.50 |
Simply Wall St.We Think Kiora Pharmaceuticals' (NASDAQ:KPRX) Healthy Earnings Might Be Conservative
Investors signalled that they were pleased with Kiora Pharmaceuticals, Inc.'s ( NASDAQ:KPRX ) most recent earnings...
NewsfileKiora Pharmaceuticals Reports Third Quarter Results; Retinal Disease Pipeline Advancing Two Phase 2 Studies
Encinitas, California--(Newsfile Corp. - November 8, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced third quarter 2024 financial results and provided an update on its pipeline of therapeutics for the treatment of retinal diseases. Key third quarter and recent corporate highlights include: Investigational new drug application approval to initiate ABACUS-2, the Phase 2 study of KIO-301, a novel molecular photoswitch, for the treatment of retinitis pig
Advertisement
Advertisement
Advertisement
© 2024 Yahoo. All rights reserved.